Genomics will revolutionize medicine



Genomics will Revolutionize Medicine

Three Reasons Quibble Genomics Will Make You Money as Genomics Changes Medicine

Quibble Image 1.jpegTargeted genetic treatments are already being developed for certain cancers. As we learn more about our DNA and how diseases are related to specific genes, diagnostic testing and medications will evolve rapidly.

Quibble Genomics is designed to take advantage of the current state of genomics – and is prepared for the developments to come.

“We are opening up the world of DNA to people,” said Dr. Rao Kotamarti, CEO of Quibble Genomics. “The power that Quibble brings and the interface that it provides is incredibly more powerful and easier to use than anything out there.”

To discover more about Quibble and its products and services, click here, or read on to see how Quibble outshines the competition in three key areas.

Machine Learning

A little more than a decade ago, researchers finished mapping the first human genome sequences. Today, thousands of genomes from a cross-section of ethnic backgrounds have been sequenced.

Soon, the information gathered from analyzing DNA is going to surpass all other forms of data. That means there will be more genetic information than all the stored data we have about the planets, the Earth itself, and all the videos on YouTube (currently the largest generator of data) combined.

This accumulation of genetic data is already presenting problems for the New York Genome Center, which is generating somewhere between 10 to 30 terabytes of DNA data every day.

“The biggest hurdle,” said Toby Bloom, deputy scientific director at the New York Genome Center, “is keeping track of what we have and finding what we need.”

Quibble is already meeting this challenge.

Quibble works by:

  • Modeling DNA sequences into compact mathematical representations
  • Storing that information in a database using organizational technology
  • Creating 3-D models of the DNA to make it easy to analyze
  • Making this information available through the easy-to-use app, GeneClues®

All of these advances are built on top of a machine-learning paradigm.

“Machine learning means that you have an algorithm and part of what it does is learn the data and organize it in a logical way,” said Dr. Kotamarti. “When the algorithm learns your DNA, it develops a signature.

“Developing a signature means, if you take 1000 Alzheimer’s patients and identify that they all have one particular gene called APOE. Now you can say what an APOE signature looks like for Alzheimer’s. If you can develop a signature for a gene, you can certainly develop a signature for a collection of genes. And if you can do that, you can develop a signature for a disease or health condition. Once you have a signature for a condition, the speed of diagnostic or screening capability will be extremely enhanced.”

With more and more genomics data entering the market everyday, being able to intelligently and automatically organize signatures gives Quibble a significant advantage over other options.

Bridging the Gap between Lab and Physician

Today, it is easier than ever for someone to get a diagnostic test. Labs like LabCorps and Quest diagnostics are ideal if you need to get your cholesterol checked. However, if your doctor wants you to get a DNA analysis, things become much more complicated.

Currently, there are only a few specialized labs across the globe equipped to perform the DNA diagnostics increasingly requested by physicians.

“We can solve that ‘last mile’ problem,” said Dr. Kotamarti. “LabCorps and Quest have the footprint, but they don’t provide these special services for every type of test. And these special labs don’t have the footprint even though they have the ability. You come to us, whether you’re LabCorp or a specialized lab, and we can bridge you to the physician and to the patients. That’s a service level differentiator that no one else can provide.”

Facilitating Personalized Medicine

There has been a rapid adoption of genomics, but it’s only a slight indication of what’s to come.

“Many physicians are behind in adapting and that’s going to change,” said Dr. Kotamarti. “The hospitals are looking to know more about their patients, and the entire healthcare system is moving toward being proactive about a patient’s health. It’s a one-way street with no way of turning back. As DNA research advances, tests and treatment options will multiply. There’s going to be more demand, there will be more people doing it, and, therefore, there’s more revenue for it.”

Quibble is designed to help users better understand their current and potential health condition. In addition, as science swiftly advances, Quibble will provide updates with the latest information relevant to someone’s specific genotype. 

“We’re helping the world transition to where it’s going to be in five to 10 years,” said Dr. Kotamarti. “Because we’re a major part of that transition while much of the market is catching up, we’re in a great spot. Our solution is based on very sound, original technology that’s quantum-computing ready because of our solution’s mathematical machine learning basis.

“The potential here is a multi-billion dollar company.”

Quibble’s innovative technology is in place as genomics transforms the world; to learn even more, click here.